
Otezla: An oral pill for plaque psoriasis, psoriatic arthritis and the mouth ulcers of Behcet's disease. It needs no routine blood tests, and it is gentler and less powerful than the injected treatments. Skyrizi: An injected biologic for moderate to severe plaque psoriasis. It blocks interleukin-23, a signal that sits high up in the psoriasis chain, and after two starting doses it is given about four times a year.


Choose for moderate psoriasis or psoriatic arthritis when you want a pill with no routine blood tests, accepting it's gentler than injections.
Choose for moderate to severe psoriasis when you want high clearance with only about four injections a year.
Can you take them together?
These are different options for psoriasis and are not usually taken together. Otezla is a tablet; Skyrizi is a more effective injection.
Compare uses by strength of evidence. Evidence level describes confidence in a benefit, not its size.











Blocks PDE4: Inhibits an enzyme that breaks down cAMP. Raises cAMP inside cells: Preserves a signal involved in regulating inflammation. Helps inflamed skin settle: Psoriasis plaques become less inflamed.
PDE4 inhibition and increased intracellular cAMP are established. The exact link to clinical improvement is not fully defined; this is a simplified overview, not every downstream pathway.

Blocks IL-23: Binds this immune messenger before it reaches its receptor. Turns down inflammatory T cells: Reduces signals that keep the psoriasis cycle active. Helps plaques clear: Excess skin buildup and inflammation gradually decrease.
Risankizumab selectively targets the p19 subunit of IL-23, not IL-12. The T-cell and skin changes are a simplified downstream interpretation.
Nothing about the dose depends on weight or on how severe your disease is. It is built up gradually only to give your stomach time to settle.
Starting dose: A five-day starter pack, beginning at 10 mg on day one and climbing in 10 mg steps, morning and evening doses in turn, until you reach 30 mg twice a day on day six.
Usual dose: 30 mg twice a day, about 12 hours apart.
If your kidneys are significantly impaired: The dose is halved to 30 mg once a day, and the starter pack is used differently.
Total course: No fixed course. It is taken as long as it helps, judged at about 16 weeks, and the benefit stops when the drug stops.
Two starting doses close together, then a long steady interval. Not adjusted for body weight.
Starting dose: 150 mg as one injection.
Second dose: 150 mg, four weeks after the first.
Usual dose: 150 mg every 12 weeks — about four injections a year after the first year.
If it stops working: There is no approved higher dose or shorter interval for psoriasis. Losing response means reviewing the diagnosis, not injecting more often.
How long: Long term, with no set end point, while it works and is tolerated.
Twice a day, roughly 12 hours apart, with or without food — food helps some people with nausea. Swallow the tablets whole; do not crush, split or chew them.
Any time of day. The calendar matters more here than with a weekly drug. Twelve weeks is long enough that people lose track, so put every dose date in your phone and book the next reminder the day you inject.
Take it out of the fridge 15 to 30 minutes before and let it warm on the counter. Cold liquid stings. No hot water, no microwave.
Inject into the front of the thigh or the belly, at least two inches from the navel. The back of the upper arm works if someone else is doing it. Rotate the site, avoid skin that is bruised, tender, hard or scarred, and never inject through a plaque. Ask for training before the first dose. Used devices go in a sharps container.
Take it as soon as you remember, unless the next dose is close, in which case skip it. Never take two at once. If you have stopped for more than a few days, ask before restarting; the full dose brings the stomach side effects straight back, so the starter pack is usually repeated.
Inject as soon as you remember, then count twelve weeks from that day. If it has been much longer than twelve weeks, call the prescriber first so the schedule can be reset.
The absence of blood tests is why many people choose this drug. No baseline blood count, no liver panel, no tuberculosis test, no hepatitis screen, nothing repeated. Kidney function is checked once before starting, because severe impairment halves the dose.
What replaces it is clinical monitoring, which is not lighter, only different. Weight comes first. Weight loss is common and can be substantial, with some people losing five to ten percent of their body weight. If you wanted that, it is welcome. If you are older, frail or already underweight, it is a reason to reconsider, and unexplained loss should prompt a review.
Mood is second. Depression, low mood and, rarely, suicidal thoughts have been reported and appear on the label. The risk is low, but new or worsening depression should be reported promptly, and a history of depression belongs on the record before you start.
Diarrhea and nausea are third. They usually settle within the first few weeks, but severe or persistent diarrhea is not something to push through. In older adults, and in anyone on a water tablet or a blood pressure medicine, it has caused dehydration and kidney injury.
The one scheduled checkpoint is the 16-week review of skin or joints. If nothing meaningful has changed, continuing is not useful.
Everyone is screened for tuberculosis before the first dose — a skin test or TB blood test, plus a chest X-ray if that is positive. Dormant TB is treated first. This class probably carries less TB risk than the TNF blockers, but screening is not optional.
Hepatitis B and C are usually checked at the same time.
After that there is no fixed blood test schedule. Risankizumab does not need the regular liver and blood count testing methotrexate does. Monitoring is clinical: the skin, whether infections are more frequent, whether the dose dates are kept. TB testing is repeated yearly or by exposure risk.
There is no boxed warning. The most common side effects reported are upper respiratory infections, headache, tiredness, fungal skin infections and injection site reactions. Serious allergic reactions are rare but are why the first dose is often given with someone trained nearby.
Approximate windows, not promises.
First doseStarting: The starter pack steps the dose up over the first week, which softens the early side effects.
Days 1 to 14Adjusting: Loose stools, nausea and headache usually start in the first week or two and settle within a month.
Weeks 2 to 4Itch: Usually the first thing to change, ahead of the plaques. Behcet's mouth ulcers settle here too, one of the faster and more reliable responses.
Weeks 4 to 8Working: The first visible change in the skin. Scale lifts before the redness fades.
Weeks 12 to 16Judge it here: In the trials roughly one in three people reached a 75 percent improvement. Scalp psoriasis responds better than thick body plaques, a common reason to choose it.
Weeks 16 to 24Psoriatic arthritis: Joint pain, swelling and tenderness improve.
Months 3 and onwardWeight and mood: Weight loss comes on gradually, so weigh yourself regularly rather than going by how clothes feel. Mood changes are uncommon but worth watching.
Months 6 and beyondNails: The slowest of all, because a nail has to grow out before improvement shows.
First few minutesThe injection: A sharp sting for a few seconds, then redness or a small welt. Settles within a day or two.
Weeks 1 to 4Starting: Itch settles first. Scale lifts and plaques thin.
Weeks 4 to 16Working: Most of the change happens here, from the second dose on. Plaques flatten and redness fades from the middle out, often leaving a paler or darker mark.
Week 16Judge it here: Most people reached 90 percent clearer skin, and many were clear or nearly clear. Joints improve on the same timeline.
3 to 6 monthsScalp, palms and soles: Slower than the trunk and limbs.
6 to 12 monthsNails: Last to change, because a nail takes months to grow out.
Between dosesSteady state: Most people notice no dip. If plaques reliably return in the last few weeks, say so.
Sorted by what to do about them.
Apremilast is expensive, priced far closer to the biologics than to older oral drugs such as methotrexate or acitretin.
So insurers commonly ask that cheaper options be tried first, and prior authorization is usual. The manufacturer runs a copay assistance program, which typically helps people with commercial insurance and is not available on government plans.
What it saves is indirect: no injection supplies, no screening tests, no repeated laboratory work. That does not close the gap with a generic tablet, but it is part of the comparison.
The list price runs to tens of thousands of dollars a year. Almost nobody pays that; what you pay depends on your plan.
It is brand only — no generic, no biosimilar — so there is no cheaper equivalent to switch to. That is a real difference from adalimumab.
Prior authorization is close to universal. Most plans require documented failure of something cheaper first — phototherapy, methotrexate, sometimes another biologic. Denials are usually about missing records rather than the drug, and appeals succeed reasonably often when the history is documented.
Manufacturer copay cards can cut the cost to very little with commercial insurance. By law they cannot be used with Medicare or Medicaid. For those plans, or no insurance, the manufacturer's patient assistance program and independent foundations are the usual routes. Terms change often.
One practical note: because doses are twelve weeks apart, a change of insurance or a formulary switch in January can land in the middle of a dosing gap. Check coverage before the next dose is due, not the week it is.
Correct. No monitoring schedule, no tuberculosis screen, no repeated bloodwork. Kidney function is checked once before starting, because severe impairment halves the dose.
For most people it is worst in the first two weeks and settles within a month, which is what the five-day starter pack softens. Diarrhea that is severe or lasts past a month is a reason to be reviewed.
Some people do, and some of them lose five to ten percent of their body weight. It happens gradually, so weigh yourself every few weeks rather than judging by how clothes fit.
Less effective for thick plaques — about one in three reached a seventy-five percent improvement at 16 weeks, where biologics reach much higher figures. What it offers is a tablet, no needles, no screening, no monitoring.
Low mood and depression are uncommon but on the label, and rare reports of suicidal thoughts exist. Report any new or worsening low mood promptly.
About 16 weeks for the skin, up to 24 weeks for joints. If nothing meaningful has changed, continuing is not worthwhile.
A large protein grown in living cells rather than a chemical made in a factory. That is why it is injected, and why it lives in the fridge.
After the first two doses, four weeks apart, yes. The drug stays in the body long enough that the gap can be twelve weeks.
A few seconds of stinging. Letting it warm to room temperature first makes a noticeable difference.
Tuberculosis and hepatitis before you start, and TB testing often repeated yearly. Beyond that, no routine schedule.
Inject when you remember and count twelve weeks from that day. If you are weeks or months late, call first.
Yes, apart from live ones. The flu shot, COVID vaccines and Shingrix are not live. Have any live ones before starting.